Celgene Quanticel Research, Inc.

Takeda Pharmaceutical Company Limited

Takeda San Diego, Inc.

Quanticel Pharmaceuticals, Inc.

Duke Manufacturing Company

Genentech, Inc.

Takeda California, Inc.

Smithkline Beecham Corporation

Array Biopharma Inc.

Burger King Corporation

Jeffrey Alan Stafford

James Marvin Veal

Toufike Kanouni

Michael Brennan Wallace

Young K Chen

Zhe Nie

Stephen W Kaldor

Stephen L Gwaltney

Jun Feng

Zhiyuan Zhang

Amogh Boloor

Sheldon Cao

Paul Isbester

Grant Jackson Palmer

Jerome C Bressi

Anthony R Gangloff

Phong H Vu

Robert J Reese

Jason W Brown

Andrew John Jennings

Qing Dong

Xiao-Yi Xiao

Gregory Glen Stettes

Juan Manuel Betancort

Nicholas Scorah

Matthew Michael Kreilein

Mingnam Tang

Laurence Edward Burgess

Christopher McBride

John David Lawson

Lynnie Lin Trzoss

Zacharia S Cheruvallath

Benjamin Jones

James W Bigott

Andre A Kiryanov

Mark Sabat

Erick Wang Co

Yan Liu

Zhe Li

Mui Cheung

Steven T Staben

Steven M Shei

Ellen Ruth Laird

Philip Anthony Harris

Richard Pastor

Matthew Volgraf

Scott Howard Dickerson

Craig Stivala

Betty Lam

John S Tyhonas

Srinivasa Reddy Natala

Bruce Joseph Elder

Luckner Gerard Ulysse

Bheema Rao Paraselli

Jonathon Stuart Salsbury

Michael John Bennett

Kim Charles Fietsam

Thomas E Kieffer

Robert Cho

David J Hosfield

Paula Alessandra Tavares-Greco

Scott D Cowen

Robert J Skene

Daryl R Monroe

Philip Gregory Geerling

Scott E Willis

Prasuna Guntupalli

Michael W McGaha

Phillip Tiberio

Ryan Stansfield

Jeongboeb Seo

Juan Manual Betancort

Beverly Lynn Wolgast

Sripathy Venkatraman

Haixia Wang

Benjamin Wann

Bingidimi Itute Mobele

Michael Robert Peel

Lily Kwok

Mallareddy Komandla

Craig A Behnke

Richard S Fornicola

Paul R Brodfuehrer

Robert Neil Hunter, Iii

Walter Keung

Yasuhisa Kohara

Victoria Feher

Maxwell M Reeve

Takashi Ichikawa

Jacek Nowakowski

Gregory Pacofsky

David Robert Jones

Shaosong Chu

Haxia Wang

Daniel Marvin Henke

Xianchang Gong

Philip Erickson

Huong-Thu Ton-Nu

Wolfgang Reinhard Ludwig Notz

Zhlyuan Zhang

An appliance having a current sensor configured to monitor load current in the appliance associated with operation of one or more components for determining a fault condition thereof. The appliance comprises a smart controller configured to control operations of the appliance and the one or more components each configured to perform an operation of the appliance in response to the smart controller. An input/output (IO) circuit coupled to the smart controller via a local data bus is configured to receive commands from the smart controller and to control the one or more components in response thereto.

Appliance component fault detection

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

Histone demethylase inhibitors

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.

Inhibitors of lysine specific demethylase-1

The present embodiments provide for substituted triazolylpyridine derivative compounds, and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for modulating the activity of histone demethylase enzymes. Additionally, the subject compounds and compositions are useful for the treatment of cancer or other neoplastic diseases, or maladies associated with abnormal histone demethylase activity. Accordingly, the substituted triazolylpyridine derivative compounds described herein are useful in methods and medicaments for treating cancer.

Dough preparation apparatus and associated methods. The dough preparation apparatus can store and be configured to execute a plurality of dough preparation recipes. In one example, the dough preparation apparatus is configured for thawing or slacking frozen dough and conditioning the dough prior to baking. The dough preparation apparatus facilitates production of baked bread having higher and more consistent quality.

Dough preparation apparatus and methods

The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1&#x3b2; and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.

Chemical compounds as inhibitors of interleukin-1 activity

Described herein is the bromodomain inhibitor 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one, including crystalline forms, amorphous forms, solvates, and hydrates thereof, as well as pharmaceutical compositions that include this bromodomain inhibitor. In some embodiments, the pharmaceutical composition comprises 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one that has been processed by micronization or spray dried dispersion. In some embodiments, the pharmaceutical composition further comprises at least one polymer. In some embodiments, the pharmaceutical composition comprises a solid polymer matrix comprising 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one and at least one polymer. Pharmaceutical compositions comprising 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one are useful for the treatment of cancer or neoplastic disease.

Bromodomain inhibitor

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

Food preparation apparatus and associated methods. In one method, dough is proofed in an oven compartment and then baked in the same oven compartment. Temperature and/or humidity can be controlled during proofing and/or baking cycles. A blower may be used, for example, to exhaust gas to ambient to reduce heat and/or moisture in the compartment. For example, the blower may be used between proofing and baking cycles to prepare an environment in the oven compartment for the baking cycle.

Food preparation apparatus and methods

The present disclosure relates to novel sulfonylurea compounds and related compounds useful in treating a disorder responsive to modulation of cytokines such as IL-1&#x3b2; and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.

Sulfonylurea compounds as inhibitors of interleukin-1 activity

The present disclosure relates generally to compositions and methods of treating neoplastic diseases or cancers, such as glioblastoma and non-Hodgkin's lymphomas, or other cancers in which the subject suffers from an advanced solid tumor, comprising a combination of, or administering a combination of, a bromodomain and extra-terminal protein (BET) inhibitor and at least one chemotherapeutic agent, which does not inhibit BET directly. The BET inhibitor/chemotherapeutic agent combination, or combination therapy, can yield synergistic effects, thereby increasing the effectiveness of the cancer treatment as compared with the administration of either the BET inhibitor or the chemotherapeutic agent alone.

Bromodomain and extra-terminal protein inhibitor combination therapy

Growing community of inventors

San Diego, CA, United States of America

Jeffrey Alan Stafford